Loading
Life sciences · Journal article
Clinical Journal of the American Society of Nephrology · September 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is a major risk factor for chronic kidney disease (CKD), which contributes to a complex interplay of metabolic, inflammatory, and hemodynamic disturbances that accelerate kidney function decline and heighten cardiovascular risk. Obesity contributes to kidney injury through direct mechanisms, including glomerular hyperfiltration and increased intraglomerular pressure, and indirect pathways mediated by diabetes, hypertension, and cardiovascular-metabolic disease, while also promoting tubular injury. Emerging evidence also suggests that adipose tissue distribution influences end-organ damage, with visceral and ectopic perirenal fat depots linked to CKD. These inter-relationships are corroborated by population-based studies showing that markers of adiposity are associated with higher risk of incident CKD, CKD progression, and end-stage kidney disease. With the advent of newer therapeutics, the management of obesity in CKD has shifted from a predominantly lifestyle-focused approach to a more comprehensive, multi-modal strategy that integrates pharmacologic therapies with established cardio-kidney-metabolic (CKM) benefits, alongside structured nutritional guidance, individualized physical activity, and sustained behavioral support. Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP1ra) and dual incretin agonists, have redefined treatment paradigms by addressing metabolic dysfunction, CKD progression, and cardiovascular risk. Emerging agents, including triple incretin agonists, promise even greater efficacy in weight reduction and metabolic control, although data on efficacy and safety in kidney disease remains limited. Sodium-glucose cotransporter 2 inhibitors also promote modest weight loss, largely through urinary glucose-mediated caloric loss, while providing cardio-kidney protection. With respect to non-pharmacological interventions, clinical studies show bariatric surgery achieves substantial weight loss and is associated with improved cardio-kidney outcomes in CKD. In this review, we examine 1) the pathophysiology of obesity-induced kidney disease and its cardio-metabolic complications, 2) risk stratification of obesity and CKD, 3) current and emerging evidence on pharmacotherapies for obesity, including practical considerations in CKD, and 4) an integrated stepwise anti-obesity management approach aligned with the CKM framework.